Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1987 2
1988 2
1989 8
1990 16
1991 8
1992 9
1993 9
1994 6
1995 11
1996 10
1997 9
1998 10
1999 9
2000 7
2001 9
2002 5
2003 13
2004 10
2005 10
2006 10
2007 11
2008 14
2009 7
2010 10
2011 4
2012 13
2013 14
2014 13
2015 10
2016 9
2017 8
2018 7
2019 13
2020 11
2021 16
2022 14
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Bang YJ, et al. Among authors: ruschoff j. Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Lancet. 2010. PMID: 20728210 Clinical Trial.
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Guccini I, Revandkar A, D'Ambrosio M, Colucci M, Pasquini E, Mosole S, Troiani M, Brina D, Sheibani-Tezerji R, Elia AR, Rinaldi A, Pernigoni N, Rüschoff JH, Dettwiler S, De Marzo AM, Antonarakis ES, Borrelli C, Moor AE, Garcia-Escudero R, Alajati A, Attanasio G, Losa M, Moch H, Wild P, Egger G, Alimonti A. Guccini I, et al. Among authors: ruschoff jh. Cancer Cell. 2021 Jan 11;39(1):68-82.e9. doi: 10.1016/j.ccell.2020.10.012. Epub 2020 Nov 12. Cancer Cell. 2021. PMID: 33186519 Free article.
Erratum zu: Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität.
Rüschoff J, Schildhaus HU, Rüschoff JH, Jöhrens K, Bocker-Edmonston T, Dietmaier W, Bläker H, Baretton G, Horst D, Dietel M, Hartmann A, Klauschen F, Merkelbach-Bruse S, Stenzinger A, Schöniger S, Tiemann M, Weichert W, Büttner R. Rüschoff J, et al. Among authors: ruschoff jh. Pathologie (Heidelb). 2023 Nov;44(Suppl 2):71-72. doi: 10.1007/s00292-023-01226-0. Pathologie (Heidelb). 2023. PMID: 37656216 Free PMC article. German. No abstract available.
ISH-based HER2 diagnostics.
Rüschoff J, Nagelmeier I, Jasani B, Stoss O. Rüschoff J, et al. Pathologe. 2021 Nov;42(Suppl 1):62-68. doi: 10.1007/s00292-020-00878-6. Epub 2020 Dec 21. Pathologe. 2021. PMID: 33346874 Review. English.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. Piccart-Gebhart MJ, et al. Among authors: ruschoff j. N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306. N Engl J Med. 2005. PMID: 16236737 Free article. Clinical Trial.
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells.
Brina D, Ponzoni A, Troiani M, Calì B, Pasquini E, Attanasio G, Mosole S, Mirenda M, D'Ambrosio M, Colucci M, Guccini I, Revandkar A, Alajati A, Tebaldi T, Donzel D, Lauria F, Parhizgari N, Valdata A, Maddalena M, Calcinotto A, Bolis M, Rinaldi A, Barry S, Rüschoff JH, Sabbadin M, Sumanasuriya S, Crespo M, Sharp A, Yuan W, Grinu M, Boyle A, Miller C, Trotman L, Delaleu N, Fassan M, Moch H, Viero G, de Bono J, Alimonti A. Brina D, et al. Among authors: ruschoff jh. Nat Cancer. 2023 Aug;4(8):1102-1121. doi: 10.1038/s43018-023-00594-z. Epub 2023 Jul 17. Nat Cancer. 2023. PMID: 37460872
[ISH-based HER2 diagnostics].
Rüschoff J, Nagelmeier I, Jasani B, Stoss O. Rüschoff J, et al. Pathologe. 2020 Nov;41(6):606-613. doi: 10.1007/s00292-020-00841-5. Pathologe. 2020. PMID: 33001242 Review. German.
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
de Vries EGE, Rüschoff J, Lolkema M, Tabernero J, Gianni L, Voest E, de Groot DJA, Castellano D, Erb G, Naab J, Donica M, Deurloo R, van der Heijden MS, Viale G. de Vries EGE, et al. Among authors: ruschoff j. Cancer Med. 2023 Jun;12(11):12071-12083. doi: 10.1002/cam4.5893. Epub 2023 Apr 29. Cancer Med. 2023. PMID: 37119523 Free PMC article. Clinical Trial.
337 results